An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

Anti-cancer Drugs
Michele ReniMassimo Falconi

Abstract

A series of 650 patients treated between 1997 and 2007 at 10 Italian centers was analyzed to assess treatment trends and efficacy in stage III pancreatic adenocarcinoma. Data on patient characteristics, treatment and outcomes were collected. The inclusion criteria were pathological diagnosis of stage III pancreatic adenocarcinoma; age more than 18 years, Eastern Cooperative Oncology Group performance status less than 3, and no past therapy. Most patients (95%) received up-front chemotherapy, which mainly consisted of gemcitabine alone (N=323), gemcitabine-based four-drug combinations (N=107), gemcitabine-platinum compound doublets (N=87), or intra-arterial gemcitabine-free triplets (N=57). The use of gemcitabine-platinum compound doublets increased over time (1997-2001: 2%; 2002-2007: 21%) whereas an inverse trend was observed for gemcitabine (71-61%). No overall survival (OS) difference was observed between patients enrolled in clinical trials and those not enrolled. The median and 1-year OS were 9.5 months and 35.5% for patients treated with gemcitabine; 8.9 months and 36.8% for those treated with gemcitabine-free intra-arterial triplets; 13.3 months and 55.8% for those treated with gemcitabine-platinating agent doublets; and...Continue Reading

References

May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ReniE Villa
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetUNKNOWN GISCAD
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher H CraneRobert A Wolff
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Volker HeinemannRalf Wilkowski
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Florence HuguetChristophe Louvet
Mar 17, 2007·International Journal of Radiation Oncology, Biology, Physics·Andrew H KoMargaret A Tempero
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael G HaddockSteven R Alberts
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Feb 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ReniE Villa
Oct 19, 2010·World Journal of Gastroenterology : WJG·Michele Reni
Sep 13, 2012·World Journal of Gastroenterology : WJG·Carmen BelliMichele Reni
Mar 27, 2012·Expert Opinion on Therapeutic Targets·Lucia LombardiEvaristo Maiello
Nov 6, 2012·Cancer Treatment Reviews·Carmen BelliMichele Reni
Feb 8, 2013·International Journal of Cancer. Journal International Du Cancer·Amir AvanElisa Giovannetti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Hedy L KindlerEverett E Vokes
The New England Journal of Medicine
John P NeoptolemosEuropean Study Group for Pancreatic Cancer
International Journal of Radiation Oncology, Biology, Physics
Valérie MagninJean Robert Delpero
© 2021 Meta ULC. All rights reserved